Figure S18 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer Article Swipe
Related Concepts
Breast cancer
Cancer research
Cancer
Oncology
Internal medicine
Medicine
Anran Chen
,
Beom-Jun Kim
,
Aparna Mitra
,
Craig T. Vollert
,
Jonathan T. Lei
,
Diana Fandino
,
Meenakshi Anurag
,
Matthew V. Holt
,
Xuxu Gou
,
Jacob B. Pilcher
,
Matthew P. Goetz
,
Donald W. Northfelt
,
Susan G. Hilsenbeck
,
C. Gary Marshall
,
Marc L. Hyer
,
Robert Papp
,
Shou-Yun Yin
,
Carmine De Angelis
,
Rachel Schiff
,
Suzanne A.W. Fuqua
,
X. Cynthia
,
Charles E. Foulds
,
Matthew J. Ellis
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1158/1535-7163.27142249
· OA: W4403044024
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1158/1535-7163.27142249
· OA: W4403044024
<p>The combination of RP-6306 and gemcitabine increases apoptosis and activates DNA damage signaling in palbociclib-resistant T47D cells</p>
Related Topics
Finding more related topics…